A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants

Safety Observation of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in Primary Immunization, Booster Immunization and Simultaneous Vaccination With Other Vaccines in Infants

The purpose of this study is to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell)(sIPV)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.

Study Overview

• Status: Completed
• Conditions: Poliomyelitis
• Intervention / Treatment: Biological: sIPV vaccine /DTaP vaccine; Biological: sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine

Detailed Description

This study is an open and observational phase Ⅳ clinical trial of Sabin Inactivated Poliovirus Vaccine.The purpose of this study is to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell)(sIPV)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.A total of 3200 subjects including 2000 subjects aged 2~3 months in primary immunization group,1200 subjects aged 18 months in primary immunization group will be enrolled and will receive sIPV vaccine or sIPV vaccine and other vaccines simultaneously.

• Study Type: Interventional
• Enrollment (Actual): 3200
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Jiangxi
    • Gao'an, Jiangxi, China, 330899
      • Gaoan Center for Disease Control and Prevention
    • Pingxiang, Jiangxi, China
      • Shangli County Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 months to 1 year (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Infants aged 2-3 months should be involved in primary immunization and they have not received Sabin strain inactivated polio vaccine (Vero Cell) in the past;
• Children aged 18 months should be immunized with the first three doses of Sabin strain inactivated polio vaccine (Vero Cell) and they have not received any inactivated or attenuated live vaccines in the past 14 days;
• The guardian agrees to sign the informed consent and voluntarily use the mobile APP to participate in the follow-up visits.

Exclusion Criteria:

• Allergic to the active ingredient in the vaccine, any inactive ingredient, or substance used in the manufacturing process;
• Allergic to this product or similar vaccines in the past;
• Patients with severe chronic diseases or allergies;
• Patients with fever or acute illness.

The Exclusion Criteria for the Second and Third Doses:

• Any serious adverse events that are causally related to vaccination;
• Severe anaphylaxis or hypersensitivity after vaccination (including hives and rashes within 30 minutes of vaccination);
• Any confirmed or suspected autoimmune or immunodeficiency disease, including human immunodeficiency virus (HIV) infection;
• Acute or newly emerging chronic diseases occur at the time of vaccination;
• Other reactions (including severe pain, severe swelling, severe limitation of movement, persistent high fever, severe headache, or other systemic or local reactions), as determined by the investigator;
• Having an acute illness at the time of vaccination (acute illness is defined as moderate or severe illness with or without fever);
• Axillary temperature >37℃ during vaccination.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Primary immunization group; A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group	Biological: sIPV vaccine /DTaP vaccine; All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
Experimental: Booster immunization group of sIPV vaccine; A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.	Biological: sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine; All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine	Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine	Within 0~7 days after primary immunization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine	Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine.	Within 0~30 days after primary immunization
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine	Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine .	Within 0~7 days after booster immunization
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine	Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine.	Within 0~30 days after booster immunization
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine	Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine.	Within 0-7 days after primary immunization combined with DTaP vaccine
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine	Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine combined with DTaP vaccine.	Within 0-30 days after primary immunization combined with DTaP vaccine
Incidence of adverse reactions after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine	Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine.	Within 0~7 days after booster immunization combined with inactivated hepatitis A vaccine
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine	Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine combined with MMR vaccine or attenuated hepatitis A vaccine.	Within 0 ~14 days after booster immunization
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine	Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.	Within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.

Collaborators and Investigators

• Sponsor: Sinovac Biotech Co., Ltd
• Investigators: Principal Investigator: Shicheng Guo, Master, Jiangxi Provincial Center for Disease Prevention and Control

Study record dates

Study Major Dates

• Study Start (Actual): June 13, 2022
• Primary Completion (Actual): September 13, 2022
• Study Completion (Actual): December 13, 2022

Study Registration Dates

• First Submitted: June 20, 2022
• First Submitted That Met QC Criteria: June 20, 2022
• First Posted (Actual): June 27, 2022

Study Record Updates

• Last Update Posted (Actual): January 12, 2023
• Last Update Submitted That Met QC Criteria: January 11, 2023
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; RNA Virus Infections; Virus Diseases; Infections; Neuromuscular Diseases; Central Nervous System Infections; Enterovirus Infections; Picornaviridae Infections; Spinal Cord Diseases; Myelitis; Poliomyelitis; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: PRO-sIPV-MA4001-JX

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No